R 0016/09 () of 19.5.2010

European Case Law Identifier: ECLI:EP:BA:2010:R001609.20100519
Date of decision: 19 May 2010
Case number: R 0016/09
Petition for review of: T 0764/06
Application number: 96924368.2
IPC class: C07D 207/34
Language of proceedings: EN
Distribution: B
Download and more information:
Decision text in EN (PDF, 94 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Crystalline R-(R*,R*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino) carbonyl-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Applicant name: Warner-Lambert Company LLC
Opponent name: Teva Pharmaceutical Industries Ltd.
LEK Pharmaceutical and Chemical Company d.d.
Board: EBA
Headnote: -
Relevant legal provisions:
European Patent Convention Art 112a(2)(c)
European Patent Convention Art 112a(2)(d)
European Patent Convention R 104
European Patent Convention R 106
Rules of procedure of the Boards of Appeal Art 12
Rules of procedure of the Boards of Appeal Art 13
Keywords: Petition for review - clearly unallowable
Catchwords:

See paragraph 2.2.13

Cited decisions:
G 0009/92
R 0021/09
Citing decisions:
R 0018/09
R 0006/11
R 0013/11
R 0019/11
R 0003/12
R 0017/14
R 0005/15
R 0006/15
R 0003/16
R 0003/17
R 0007/18
T 0453/08
T 0160/09
T 0028/10
T 0253/10
T 0518/10
T 1788/10
T 2197/10
T 2436/10
T 0484/11
T 2016/11
T 0409/12
T 1635/13
T 0205/14
T 2256/14
T 1533/15
T 2352/15
T 2600/17

Source: http://www.epo.org/law-practice/case-law-appeals/recent/r090016eu1.html

Date retrieved: 17 May 2021

32 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

Case Law Book: V Priority

Case Law of the Enlarged Board

General Case Law